HumanFirst, a cloud-based software company accelerating patient-centered drug development through AI-powered insights, announced the launch of the industry’s first-of-its-kind precision measures platform. HumanFirst’s platform enables pharma and biotechs to reliably incorporate patient-centric measures and validated technologies into clinical research.
With life science organizations under pressure to increase R&D efficiency and participant diversity, AI-powered biomarkers and COAs are poised to revolutionize drug development. Recent regulatory support for AI-powered measures and sensor-derived primary endpoints from the Food and Drug Administration and the EMA has rapidly accelerated biopharma’s investment in AI strategies, with the potential for huge patient impact.
To address this critical need, HumanFirst has evolved its longstanding Atlas platform – previously the most comprehensive data map for evidence-backed digital health technologies (DHTs) used in clinical research – to a cloud-based enterprise platform for precision measures spanning DHTs, questionnaires, blood and fluid-based markers, and imaging.
Life science organizations seeking to accelerate drug development by investing in AI can now partner with HumanFirst to access:
- Atlas Network: The most comprehensive evidence platform for precision measures. Curating more than 7,500+ pieces of evidence, including 1,700 clinical trials by hundreds of sponsors, Atlas allows teams to select, collaborate on and deploy the right measures from its database of 15,000+ digital measures, and thousands of DHTs, questionnaires, and blood and fluid-based markers.
- Atlas Connect: Private and secure workflow solution for organizations to manage their own proprietary research data and work collaboratively across their teams, accelerating protocol development
- Atlas Insights: AI-powered insights, analysis, and curated evidence to enable differentiated asset and portfolio strategies
- HumanFirst Institute: Purposefully crafted to educate and empower research teams on best practices to unlock the benefits of precision measures and AI in clinical trials. The Institute equips teams with the essential knowledge, training and network needed to deploy an effective precision measurement strategy to bring better, patient-centered treatments to market, faster
“We at HumanFirst have been, and continue to be, the single largest database of AI-powered biomarkers and COAs, with our data that tracks research from more than 850 sponsors. As navigating AI has become an imperative for all of pharma, I’m excited that with today’s announcement, HumanFirst now offers a solution for the entire enterprise to reduce costs, accelerate development, and bring better treatments to market faster,” said Andy Coravos, co-founder and CEO of HumanFirst.
SOURCE: PRNewswire
